MS drug ocrelizumab gets a Needle-Free makeover: new shot form tested
NCT ID NCT07667322
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new way to give ocrelizumab (Ocrevus) for multiple sclerosis — as a simple shot under the skin instead of a long IV infusion. About 75 adults with MS will receive increasing doses to see if the new form is safe and tolerable. If it works, it could make treatment much more convenient.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ocrelizumab (Ocrevus) given as a shot under the skin
What this could lead to
If successful, this could offer a more convenient way to take ocrelizumab for multiple sclerosis, potentially reducing infusion time and side effects.
What could go wrong
This is an early Phase 1 trial with only 75 people, so safety and effectiveness are not yet proven. The new injection form may cause different side effects or not work as well as the current IV version.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centro de Investigacion Medico Biologico y Terapia Avanzada, S.C.
RECRUITINGGuadalajara, Jalisco, 44130, Mexico
-
Centro de Pesquisas Clinicas
ACTIVE_NOT_RECRUITINGSão Paulo, São Paulo, 01228-200, Brazil
-
Hope Neurology
ACTIVE_NOT_RECRUITINGKnoxville, Tennessee, 37922, United States
-
Inovacion y Desarrollo en ciencias de la salud
ACTIVE_NOT_RECRUITINGMexico City, Mexico CITY (federal District), 14090, Mexico
-
Instituto de Neurologia de Curitiba
ACTIVE_NOT_RECRUITINGCuritiba, Paraná, 81210-310, Brazil
-
John Hopkins University School of Medicine
ACTIVE_NOT_RECRUITINGBaltimore, Maryland, 21287, United States
-
Morriston Hospital
ACTIVE_NOT_RECRUITINGSwansea, SA6 6NL, United Kingdom
-
Neurology Associates, PA
ACTIVE_NOT_RECRUITINGMaitland, Florida, 32751, United States
-
Nottingham University Hospitals NHS Trust
ACTIVE_NOT_RECRUITINGNottingham, NG7 2UH, United Kingdom
-
Profound Research, LLC
ACTIVE_NOT_RECRUITINGCarlsbad, California, 92011, United States
-
Shepherd Center Inc.
ACTIVE_NOT_RECRUITINGAtlanta, Georgia, 30309, United States
-
University of South Florida
ACTIVE_NOT_RECRUITINGTampa, Florida, 33612, United States